Ask EASL is an ongoing series of educational podcasts dedicated to answering questions from patients and patient organisations on important topics around liver disease.

In this episode, Professor Markus Cornberg is joined by Dr Christiane Eberhardt and Professor Daniel Shouval to answer a range of questions raised by EASL’s Patient Synergies regarding the recently approved COVID-19 vaccinations. They address topics including the reasons for the rapid development of the vaccines, whether immunocompromised liver transplant patients should receive the vaccine, real-world data from vaccination programmes worldwide and the potential duration of immunity.

 

podcast

 

This podcast is also available on the following platforms:

spotify Apple Tunein

 

Biographies

Markus Cornberg

Markus Cornberg is Professor of Infectious Diseases with a focus on hepatology and Senior Consultant at the Department of Gastroenterology, Hepatology and Endocrinology at the Hanover Medical School, Hanover, Germany. He has been Clinical Director of Helmholtz Centre for Infection Research and Director of the Centre for Individualized Infection Medicine (CIIM) since 2019. His clinical focus is the treatment of patients with infectious liver diseases and his research focus is the investigation of cellular immune responses for disease progression and treatment response in patients with viral hepatitis.

Christine Eberhardt

Christiane Eberhardt is a physician-scientist with a background in vaccine-immunology. She is currently working as clinical vaccinologist at the Center for Vaccinology in Geneva, Switzerland, where she focusses her work on the vaccine follow-up of adult transplant patients. She conducted a policy-changing clinical study on the timing of maternal pertussis immunization, a work that was awarded several prizes. She currently works on assessing the ontogeny of B-cell responses in early life and the immune responses to SARS-CoV-2 infection and vaccination.

Daniel Shouval

Daniel Shouval is Emeritus Professor of Medicine at the Hebrew University Faculty of Medicine in Jerusalem, Israel and former Dean of the Faculty. He is a standing adviser to the European Viral Hepatitis Prevention Board and the World Health Organization. A recipient of EASL’s recognition award, Professor Shouval served as EASL’s honorary president of ILC in 2016. His main research interests include the biology of, and immune response to, hepatitis B and A virus infection and liver tumours.